Disclosed herein is a perfusion filtration module or bioreactor for filtering a fluid, wherein the filtration module or bioreactor has a plurality of hollow fiber filter membranes that are splayed to reduce fouling of the filtration array.

Provided is a method for large-scale preparation of a purified preparation of a recombinant lentiviral vector at the GMP grade. The method comprises: (a) providing raw material feed liquid to be purified that comprises recombinant viral vectors; (b) carrying out a microfiltration treatment on the feed liquid to obtain a microfiltered filtrate comprising the recombinant viral vectors; (c) optionally concentrating the filtrate to obtain a concentrated filtrate; (d) purifying the filtrate obtained in the previous step by means of chromatography to obtain a crude pure product comprising the recombinant viral vectors; and (e) subjecting the crude pure product obtained in the previous step to liquid exchange and elaborate purification to obtain the purified recombinant viral vectors.

The present invention provides a novel sialo-sugar chain, a process for producing the sialo-sugar chain, and a device for producing the sialo-sugar chain. A sialo-sugar chain can be easily and efficiently mass-produced by reacting a sugar wherein a hydroxy groups is substituted with an alkynyl group (herein sometimes referred to as “alkynylated sugar”) with a specific sialic acid donor in the presence of a sialic acid-introducing enzyme.

Disclosed herein is a perfusion filtration module or bioreactor for filtering a fluid, wherein the filtration module or bioreactor has a plurality of hollow fiber filter membranes that are splayed to reduce fouling of the filtration array.

The present invention relates to cell free protein manufacturing, and more particularly, for integrating machine learning into a portable cell-free bioprocessing system for producing proteins with increased and consistent purity, potency and quality wherein such proteins are prepared on-demand and for point-of-care delivery.

The invention provides systems, modules, bioreactor and methods for the automated culture, proliferation, differentiation, production and maintenance of tissue engineered products. In one aspect is an automated tissue engineering system comprising a housing, at least one bioreactor supported by the housing, the bioreactor facilitating physiological cellular functions and/or the generation of one or more tissue constructs from cell and/or tissue sources. A fluid containment system is supported by the housing and is in fluid communication with the bioreactor. One or more sensors are associated with one or more of the housing, bioreactor or fluid containment system for monitoring parameters related to the physiological cellular functions and/or generation of tissue constructs; and a microprocessor linked to one or more of the sensors. The systems, methods and products of the invention find use in various clinical and laboratory settings.

A fluid transfer system includes a transfer carousel capable of rotational and/or translational movement; at least one holding vessel (e.g. syringe) having a plunger, wherein the syringe is connected to the transfer carousel such that the movement of the transfer carousel results in movement of the syringe and wherein the syringe is capable of translational movement relative to the transfer carousel; a drive motor connected to the syringe that is capable of controlling the position of the plunger; and a peripheral module comprising at least one vessel that is capable of containing a fluid, wherein the vessel has an opening that can be mated with the syringe to allow fluid transfer between the vessel and the syringe. Methods for transferring a fluid are also disclosed.

The present disclosure relates to hollow fiber tangential flow filters, including hollow fiber tangential flow depth filters, for various applications, including bioprocessing and pharmaceutical applications, systems employing such filters, and methods of filtration using the same.

The present invention relates to: a method in which extracellular vesicles with improved therapeutic efficacy are produced from a three-dimensional spheroid-type cell aggregate produced using a microwell having a particular structure; and extracellular vesicles produced by the production method. When the method for producing extracellular vesicles, according to the present invention, is used, extracellular vesicles having enhanced efficacy can be mass-produced, and the produced extracellular vesicles include higher levels of various efficiency factors than existing extracellular vesicles and exhibit uniform characteristics without difference between donors, and thus can be used for various purposes in the medical industry.

The present invention is directed to the development of continuous processing technology for the purification of biopharmaceuticals and biological products, such as monoclonal antibodies, protein therapeutics, and vaccines. Methods for continuous processing of a biological product in a feed stream toward formulation of a purified bulk product are described.